Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCheckit Regulatory News (CKT)

Share Price Information for Checkit (CKT)

Share Price is delayed by 15 minutes
Get Live Data
25.00    0.00 (0.00%)
Bid:
24.00
Ask:
26.00
Spread: 2.00 (8.333%)
Market Cap: £27.00m
CKT Live PriceLast checked at - London Stock Exchange

Intraday Checkit Share Chart

Trading Statement

8 Feb 2018 07:00

RNS Number : 2486E
Elektron Technology PLC
08 February 2018
 

Elektron Technology plc

(AIM: EKT, "Elektron" or the "Group")

Trading update

Elektron Technology plc, the global technology group, is pleased to provide an update on trading for the financial year ended 31 January 2018.

Group Trading

Group revenue from continuing operations for the full year is expected to be approximately £30.5m (unaudited) a 10.9% increase compared with £27.5m (on a like for like basis) for the previous year, returning the business to growth. Trading in the second half of the year from continuing operations, was substantially stronger than the first half as a result of the conversion of Bulgin's strong H1 order book to sales revenue. Revenue from continuing operations in the second half was £16.6m (unaudited) compared with £13.9m (unaudited) in the first half. Underlying trading performance from continuing operations benefitted from the operational gearing effect of increased sales over the prior year, improved Bulgin margins and efficiency improvements.

Sales

Sales from continuing operations* £m

Unaudited

FY 2018

FY 2017

% change

Bulgin

27.3

24.1

+13.3%

IMC (Queensgate and Elektron Eye Technology)

2.7

3.1

-12.9%

Checkit

0.5

0.3

+66.7%

Total Sales

30.5

27.5

+10.9%

* Excludes businesses disposed of during the year

Orders

Orders received in the year* £m

Unaudited

FY 2018

FY 2017

% change

Bulgin

29.3

25.7

+14.0%

IMC (Queensgate and Elektron Eye Technology)

3.8

2.4

+58.3%

Total Orders

33.1

28.1

+17.8%

*Checkit is excluded from the above table owing to its recurring revenue, subscription based model. Contracted recurring revenue (comprising already installed systems and those scheduled to be installed) as at 31 January 2018 was >£750k per annum (2017: £270k), an increase of 178%.

Bulgin

Bulgin ended the period with both sales and orders significantly ahead of the prior year. This was driven by the record level of sales made in the third quarter, however sales in the last quarter of the year returned to normalised levels. During the year Bulgin successfully launched its new "M-series" connector generating in excess of £500k of sales. Bulgin's fibre optic connector ranges are set for launch during the first half of this year.

IMC (Queensgate and Elektron Eye Technology ("EET"))

The sales decline in IMC was primarily due to destocking in EET in the early part of the year. Following a review of EET's commercial strategy, progress has been made in developing the EET global distribution channel. This is reflected in the full year order position which is significantly ahead of the prior year. During the year and as previously announced, EET acquired all IP relating to its product suite. EET also received notification from the US Food and Drug Administration (FDA) that the Henson 9000 is not subject to premarket registration under its clearance procedures thus paving the way for establishing a distribution network in the US.

Owing to the long term and unpredictable nature of the projects in which Queensgate operates, it was only able to deliver a modest increase in revenues. It does however start the new financial year with a significantly higher order book than a year ago.

Medical Service, a legacy element of the Agar Medical business which was closed in 2016 and was involved in servicing of medical devices, has now closed as planned. It was a marginal revenue and brand contributor to the Group and its revenues are no longer to be treated as part of continuing operations.

Checkit

Checkit continues to make progress with its real time operations management product suite. In particular, the adoption of Checkit has begun in two of the world's largest facilities management companies that employ over 1 million people between them. In addition, discussions are underway with several national and multi-national food service chains.

Cash

Group net cash was approximately £5.1m at 31 January 2018 (31 January 2017: £1.0m,) driven by a strong trading performance and the receipt of £1.9m cash proceeds from the Group's disposal process (namely Sheen Instruments, Digitron and Titman Tip Tools).

Outlook

The new financial year commenced with an order book in excess of £9m (unaudited) compared with £5.9m (unaudited) in the prior year.

The disposal programme has enabled management to focus solely on the businesses which the Board believes offer greatest potential for growth and realisation of significant shareholder value.

The Group plans to maintain its stated focus on new product development and expects to further invest during FY19 in order to continue to grow and maintain the momentum in the established and fledgling growth businesses.

John Wilson, Chief Executive Officer of Elektron, said:

"The business has delivered on its stated objective of returning the business to growth and starts the year with a strong order book. The Group is well positioned to continue to capitalise on the many opportunities available."

For further enquiries:

 

 

Elektron Technology plc

+44 (0) 1223 371 000 

www.elektron-technology.com

John Wilson (Chief Executive Officer)

Andrew Weatherstone (Chief Financial Officer & Company Secretary)

 

 

 

N+1 Singer (Nominated Adviser & Broker)

Shaun Dobson / Jen Boorer (Corporate Finance)

 +44 (0) 20 7496 3000 

Michael Taylor (Corporate Broking)

 

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

 

 

Notes to Editors:

Elektron conceives, designs and markets innovative products and services for business that connect, monitor and control. We have a multi skilled team of engineers, software and product line specialists based in Cambridge focused on the opportunities created by global growth in the following areas:

- Demand for ubiquitous power and data: Bulgin

- Real-time operations management using Internet of Things (IoT) technology: Checkit

- Screening for the effects of ageing on sight: Elektron Eye Technology

- High precision nano-scale manufacture: Queensgate

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTBCGDDLGGBGIR
Date   Source Headline
10th Aug 20237:00 amRNSTrading update notice of results & contract
8th Jun 20234:08 pmRNSResult of AGM
24th May 20233:29 pmRNSDirector/PDMR Shareholding
15th May 20231:04 pmRNSPosting of Annual Report and Notice of AGM
24th Apr 20237:00 amRNSPreliminary Results
13th Apr 20231:36 pmRNSNotice of Results and Investor Presentation
23rd Mar 20235:25 pmRNSDirector/PDMR Shareholding
13th Mar 20238:55 amRNSStatement re. Silicon Valley Bank
16th Feb 20237:00 amRNSTrading Update and Notice of Results
26th Jan 20234:10 pmRNSDirectorate Change
23rd Jan 20237:00 amRNSDirector/PCA Dealing
10th Jan 20237:00 amRNSAppointment of Non-Executive Director
10th Jan 20237:00 amRNSGrant of options and PDMR dealings
5th Jan 20237:00 amRNSContract wins and investor presentation
12th Dec 20225:14 pmRNSDirector/PDMR Shareholding
27th Sep 202212:28 pmRNSHolding(s) in Company
23rd Sep 20226:16 pmRNSDirector/PDMR Shareholding
16th Sep 20225:36 pmRNSDirector Dealing
15th Sep 20227:00 amRNSInterim Results
6th Sep 20227:00 amRNSInvestor Presentation
22nd Aug 20221:07 pmRNSDirector/PDMR Shareholding
11th Aug 20227:00 amRNSTrading Update and Notice of Interim Results
9th Jun 20223:09 pmRNSResult of AGM
13th May 20225:17 pmRNSPosting of Annual Report and Notice of AGM
13th May 20227:00 amRNSInvestor Conference
4th May 20227:00 amRNSContract Renewal
28th Apr 20227:00 amRNSPreliminary Results
29th Mar 20227:00 amRNSGrant of options and PDMR dealings
23rd Feb 20227:00 amRNSPDMR Dealing
22nd Feb 20227:00 amRNSPDMR Dealing
17th Feb 20227:00 amRNSTrading update
1st Feb 20227:00 amRNSContract win
22nd Dec 20212:06 pmRNSHolding(s) in Company
20th Dec 20217:01 amEQSCheckit (CKT): SaaS software for the deskless workforce
17th Dec 20212:44 pmRNSDirector/PDMR Shareholding
16th Dec 202111:52 amRNSResult of General Meeting and Admission
2nd Dec 202111:00 amRNSHolding(s) in Company
2nd Dec 202111:00 amRNSHolding(s) in Company
29th Nov 202111:44 amRNSPosting of Circular and Notice of General Meeting
26th Nov 20212:23 pmRNSResult of Placing
26th Nov 20217:00 amRNSProposed Placing
28th Oct 20217:00 amRNSContract win
16th Sep 20217:00 amRNSInterim Results
12th Aug 20217:00 amRNSTrading Update and Notice of Interim Results
6th Aug 20213:13 pmRNSDirector/PDMR Shareholding
15th Jul 20217:00 amRNSProduct Update
13th Jul 20215:08 pmRNSGrant of options and PDMR dealings
12th Jul 20217:00 amRNSAppointment of Chief Executive Officer
29th Jun 20214:01 pmRNSCapital Markets Day
10th Jun 20219:16 amRNSPDMR Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.